Drugs / KDSTEM Inj.
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06071143 | Feb 2024 → Mar 2026 | chronic kidney disease | EHL Bio Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KDSTEM Inj. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06071143 ↗ |
| Modality | Cell therapy | “autologous urine-derived stem cells” NCT06071143 ↗ |
| Route | Intravenous | “injected intravenously three times over the duration of the study.” NCT06071143 ↗ |